Unicycive Therapeutics was started by a single person, went public through an IPO in 2021, and four years later is preparing to continue its track record of proving skeptics wrong by independently launching its first drug.
Unicycive Approaches Its First Approval, But In A Competitive Space
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
